Concepedia

Author

Dee Lin

Janssen Scientific Affairs (United States)ORCID

Also Known As

D. Lin, Dee Lin

67

Publications

439

Citations

12

H-Index

13

Concepts

All Affiliations

Janssen Scientific Affairs (United States)Janssen (United States)Group for Research in Decision AnalysisLexicon Pharmaceuticals (United States)Sanofi (United States)
DL

About

Dee Lin is an author at Janssen Scientific Affairs (United States) specializing in psychiatry, public health, and psychopathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

31

2

Public Health

2

2

31

3

Health Policy

2

2

31

4

Psychiatry

2

2

31

5

Rehabilitation

1

1

18

Dee Lin

×

15

Publications

262

Citations

12

H-Index

YearCitations

Unemployment, homelessness, and other societal outcomes in patients with schizophrenia: a real-world retrospective cohort study of the United States Veterans Health Administration database

Dee Lin, Hyunchung Kim, Keiko Wada,

BMC Psychiatry

2022

39

Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States

Dee Lin, Kruti Joshi, Alexander Keenan,

Frontiers in Psychiatry

2021

31

Estimation of Annual Health Care Costs for Adults with Type 1 Diabetes in the United States

Vijay N. Joish, Fang Liz Zhou, Ronald Preblick,

Journal of Managed Care & Specialty Pharmacy

2020

27

Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries

Dominic Pilon, Charmi Patel, Marie‐Hélène Lafeuille,

Current Medical Research and Opinion

2021

23

Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies

Christoph U. Correll, Carmela Benson, Bruno Émond,

Schizophrenia

2023

18

Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study

Charmi Patel, Bruno Émond, Laura Morrison,

Current Medical Research and Opinion

2021

17

Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse

Maryia Zhdanava, Dee Lin, Marie‐Hélène Lafeuille,

Clinical Therapeutics

2021

13

The Impact of Once-Monthly Paliperidone Palmitate on Healthcare Utilization Among Patients With Schizophrenia Treated in an Integrated Healthcare System: A Retrospective Mirror-Image Study

Rohan Mahabaleshwarkar, Dee Lin, Jesse Fishman,

Advances in Therapy

2021

13

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration

Tyler B. Sandahl, Scott A. Soefje, Rafaël Fonseca,

JCO Oncology Practice

2024

13

Evaluation of alterations in serum immunoglobulin concentrations in components of metabolic syndrome, obesity, diabetes, and dyslipidemia

Dee Lin, Mary Barna Bridgeman, Luigi Brunetti

BMC Cardiovascular Disorders

2019

12

Page 1